India Rejects Patent Bid For Drug-Resistant TB Treatment Regimen

The Indian Patent Office has officially rejected a patent application filed by the U.S.-based Global Alliance for TB Drug Development, widely known as the TB Alliance. The application sought proprietary rights over the combination of bedaquiline, pretomanid, and linezolid—known as BPaL—which forms a critical six-month, all-oral treatment regimen for drug-resistant tuberculosis. Public health advocates, patient networks, and legal aid groups immediately lauded the ruling as a major victory for medical affordability and patient access.

This high-stakes regulatory decision arrives against the backdrop of India bearing the world’s most severe tuberculosis burden. According to World Health Organization estimates, approximately 2.71 million people developed the disease in India in recent years, representing roughly a quarter of all global cases. For millions of vulnerable patients, the availability of generic, affordable medications is not merely a matter of economic policy, but a critical lifeline determining survival and recovery.

Legal Grounds and Opposition Mechanics

The formal rejection was the culmination of aggressive legal challenges initiated years prior. In 2020, two distinct pre-grant oppositions were filed against the TB Alliance application. The first was spearheaded by Eldred Tellis of the Sankalp Rehabilitation Trust and Ganesh Acharya, with critical support from the Lawyers’ Collective and the Médecins Sans Frontières Access Campaign. The second opposition was filed by the Delhi Network of Positive People (DNP+) with support from the Third World Network (TWN).

The opposing parties systematically argued that combining bedaquiline, pretomanid, and linezolid into a shorter therapeutic course did not constitute an inventive step. They pointed out that the individual medicines and their combined utility had already been disclosed in public scientific literature and clinical trials dating back to 2015. Consequently, granting a patent monopoly would reward the packaging of pre-existing knowledge rather than genuine pharmaceutical innovation.

Upholding these arguments, the Indian Patent Office applied foundational safeguards enshrined within India’s Patents Act. The office confirmed violations under Section 3(d), which restricts patents on new uses of known substances, Section 3(e), which excludes mere admixtures, and Section 3(i), which bars patents on methods of medical treatment. Furthermore, regulators agreed that the patent application failed to sufficiently disclose the claimed invention, cementing a comprehensive defeat for the applicant.

Pharmacological Mechanisms of BPaL

To fully grasp the pharmacological dimensions of the BPaL regimen, it is necessary to examine how these three distinct molecular entities interact to combat Mycobacterium tuberculosis. Drug-resistant strains, particularly multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) variants, develop genetic mutations that neutralize standard first-line therapies such as isoniazid and rifampicin. The BPaL architecture bypasses these resistance pathways by deploying three advanced compounds with complementary mechanisms of action.

Bedaquiline functions as a diarylquinoline antimycobacterial agent. Its primary mechanism involves the specific inhibition of mycobacterial ATP synthase, an essential enzyme required for energy generation in the bacterium. By halting ATP synthesis, bedaquiline starves the pathogen of energy, effectively killing both replicating and dormant bacilli. Pretomanid belongs to the nitroimidazooxazine class, acting as a respiratory poison and inhibitor of mycolic acid synthesis under both aerobic and anaerobic conditions inside the hypoxic environment of lung lesions. Linezolid, an oxazolidinone antibiotic originally developed to combat Gram-positive bacterial infections, inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit.

The technical breakthrough claimed by developers was not the creation of these individual molecules, but rather their synchronized administration to target multiple metabolic pathways simultaneously. This synergistic suppression prevents the bacterium from acquiring secondary mutations during therapy. However, because these individual pharmacological properties and their combinatorial application were already documented in peer-reviewed literature prior to the patent filing, patent examiners ruled that the formulation lacked the mandatory technical novelty required under Indian intellectual property statutes.

Market Dynamics and Global Benchmarks

The Indian Patent Office’s decision sends immediate shockwaves through the global pharmaceutical market, directly altering the competitive landscape for second-line and third-line tuberculosis therapeutics. Enterprise competitors, particularly generic active pharmaceutical ingredient manufacturers based in India, are now legally empowered to produce and market the BPaL regimen without facing infringement litigation or paying prohibitive licensing royalties. This structural shift dismantles proprietary pricing models and introduces robust market competition, which historically drives down drug costs significantly.

When evaluated against global industry benchmarks, India’s regulatory stance contrasts sharply with intellectual property frameworks in the United States and the European Union, where secondary patents on drug combinations are frequently granted. In Western markets, extended patent protection often allows pharmaceutical originators to maintain high price points for years after the core molecule’s patent has expired—a practice commonly termed evergreening. By rigidly enforcing Section 3(d) of the Patents Act, India acts as a vital global benchmark for developing nations, ensuring that public health imperatives supersede corporate revenue generation.

For international procurement agencies such as the Global Fund and the Stop TB Partnership, the elimination of patent barriers in India drastically simplifies supply chain economics. Generic manufacturers can now scale up production, enabling bulk procurement at significantly lower per-patient costs. This ensures that cash-strapped public health systems across Africa, Latin America, and Southeast Asia can acquire life-saving treatments for thousands more patients within existing budgetary constraints.

The Public Health Impact of Shorter Treatment Regimens

To understand the gravity of this decision, one must examine the grueling physical and psychological toll of legacy tuberculosis treatments. Traditional protocols for drug-resistant strains historically forced patients into regimens lasting well over a year, frequently requiring painful daily injections that caused severe side effects, interrupted employment, and fractured family structures.

The WHO-recommended BPaL regimen transforms this landscape by offering a concise, six-month, all-oral course of treatment. Loon Gangte of DNP+ emphasized the human dimension of this medical advancement, noting that only those who have survived long-term antibiotic therapies understand the profound relief of reclaiming their lives, returning to work, and caring for dependents without the shadow of debilitating drug toxicity.

By preventing a private entity from locking this combination behind a restrictive patent wall in India, the regulatory ruling ensures that generic manufacturers can produce and distribute the regimen affordably. This mirrors how systemic innovations ultimately derive their true societal value from widespread, unhindered clinical adoption.

Frequently Asked Questions

What is the BPaL regimen and why is it important?

The BPaL regimen is a combination of three drugs—bedaquiline, pretomanid, and linezolid—administered as a six-month, all-oral treatment for drug-resistant tuberculosis. It is critically important because it drastically shortens treatment duration and eliminates painful injections required by older protocols.

Why did the Indian Patent Office reject the patent application?

The patent office rejected the application because the combination of these known medicines and its shorter use had already been disclosed in prior scientific research and clinical trials. The application violated Sections 3(d), 3(e), and 3(i) of India’s Patents Act regarding known substances, admixtures, and methods of medical treatment.

What are civil society groups demanding next?

Following the Indian ruling, patient and advocacy networks are urging the U.S.-based TB Alliance to voluntarily surrender granted patents and withdraw pending applications across other countries where patents were secured.

Do international patents for BPaL still exist outside India?

Yes, the TB Alliance holds patents for the BPaL combination in 11 other countries, including Russia, South Africa, Indonesia, and Azerbaijan, with protections extending until 2036. Civil society organizations are actively campaigning for the voluntary surrender of these international patents.

Sources and further reading

Read the original investigative report on The Hindu.